Claims
- 1. A compound of the formula: ##STR11## wherein: n is 1 or 2,
- R is a hydrogen atom or an H--(C.sub.1 -C.sub.8)-alkylene, hydroxy-(C.sub.1 -C.sub.8)-alkylene, R.sup.1 R.sup.2 N--(C.sub.1 -C.sub.8)-alkylene, R.sup.1 R.sup.2 N--(C.sub.1 -C.sub.8)-alkylene-co, R.sup.1 R.sup.2 N--CO--NR.sup.3 --(C.sub.1 -C.sub.8)-alkylene, or R.sup.1 R.sup.2 N--CO-- radical,
- R.sup.1 is a hydrogen atom or a straight-chained or branched, saturated or unsaturated radical containing 1 to 6 carbon atoms or a cyclic alkyl radical containing 3 to 6 carbon atoms,
- R.sup.2 is a hydrogen atom or a straight chain or branched, saturated or unsaturated radical containing 1 to 6 carbon atoms or a cyclic alkyl radical containing 3 to 6 carbon atoms
- R.sup.3 is a hydrogen atom or a straight chained or branched, saturated or unsaturated radical containing 1 to 6 carbon atoms, or a cyclic alkyl radical containing 3 to 6 carbon atoms,
- A is a valency bond or a --NR.sup.4 --CO-- or --CO--NR.sup.4 -- radical in which R.sup.4 is a hydrogen atom or a straight chain or branched, saturated or unsaturated radical containing 1 to 6 carbon atoms or a cyclic alkyl radical containing 3 to 6 carbon atoms, and
- B is a straight chained or branched alkylene chain containing 1 to 8 carbon atoms, in which a --CH.sub.2 -- group can be replaced by a cycloalkylene radical containing 3 to 6 carbon atoms, with the proviso that R cannot be a R.sup.1 R.sup.2 N--(C.sub.1 -C.sub.8)-alkylene-CO-- or R.sup.1 R.sup.2 N--(C.sub.1 -C.sub.8)-alkylene radical in which R.sup.1 and R.sup.2 are both hydrogen atoms,
- or an optically-active isomer thereof or a pharmaceutically acceptable salt thereof.
- 2. A compound of the formula: ##STR12## wherein: n is 1 or 2,
- R is a hydrogen atom or an H--(C.sub.1 -C.sub.8)-alkylene, hydroxy-(C.sub.1 -C.sub.8)-alkylene, R.sup.1 R.sup.2 N--(C.sub.1 -C.sub.8)-alkylene, R.sup.1 R.sup.2 N--(C.sub.1 -C.sub.8)-alkylene-CO, R.sup.1 R.sup.2 N--CO--NR.sup.3 --(C.sub.1 -C.sub.8)-alkylene, or R.sup.1 R.sup.2 N--CO-- radical,
- R.sup.1 is a hydrogen atom or a straight-chained or branched, saturated or unsaturated radical containing 1 to 6 carbon atoms or a cyclic alkyl radical containing 3 to 6 carbon atoms,
- R.sup.2 is a hydrogen atom or a straight chain or branched, saturated or unsaturated radical containing 1 to 6 carbon atoms or a cyclic alkyl radical containing 3 to 6 carbon atoms
- R.sup.3 is a hydrogen atom or a straight chained or branched, saturated or unsaturated radical containing 1 to 6 carbon atoms, or a cyclic alkyl radical containing 3 to 6 carbon atoms,
- A is a --NR.sup.4 --CO-- or --CO--NR.sup.4 -- radical in which R.sup.4 is a hydrogen atom or a straight chain or branched, saturated or unsaturated radical containing 1 to 6 carbon atoms or a cyclic alkyl radical containing 3 to 6 carbon atoms, and
- B is a straight chained or branched alkylene chain containing 1 to 8 carbon atoms, in which a --CH.sub.2 -- group can be replaced by a cycloalkylene radical containing 3 to 6 carbon atoms, with the proviso that R cannot be a R.sup.1 R.sup.2 N--(C.sub.1 -C.sub.8)-alkylene or R.sup.1 R.sup.2 N--(C.sub.1 -C.sub.8)-alkylene-CO-- radical in which R.sup.1 and R.sup.2 are both hydrogen atoms,
- or an optically-active isomer thereof; or a pharmaceutically acceptable salt thereof.
- 3. The compound of claim 1, wherein B is a straight or branched alkylene chain containing up to 8 carbon atoms.
- 4. The compound of claim 1, wherein R is methyl and B is ethylene.
- 5. The compound according to claim 1, which is N-(1-methylpiperidin-4-yl)-4-nitroxybutyric acid amide.
- 6. A pharmaceutical composition suitable for the treatment of angina, comprising a compound of the formula: ##STR13## wherein: n is 1 or 2,
- R is a hydrogen atom or an H--(C.sub.1 -C.sub.8)-alkylene, hydroxy-(C.sub.1 -C.sub.8)-alkylene, R.sup.1 R.sup.2 N--(C.sub.1 -C.sub.8)-alkylene, R.sup.1 R.sup.2 N--(C.sub.1 -C.sub.8)-alkylene-CO, R.sup.1 R.sup.2 N--CO--NR.sup.3 --(C.sub.1 -C.sub.8)-alkylene, or R.sup.1 R.sup.2 N--CO-- radical,
- R.sup.1 is a hydrogen atom or a straight-chained or branched, saturated or unsaturated radical containing 1 to 6 carbon atoms or a cyclic alkyl radical containing 3 to 6 carbon atoms,
- R.sup.2 is a hydrogen atom or a straight chain or branched, saturated or unsaturated radical containing 1 to 6 carbon atoms or a cyclic alkyl radical containing 3 to 6 carbon atoms
- R.sup.3 is a hydrogen atom or a straight chained or branched, saturated or unsaturated radical containing 1 to 6 carbon atoms, or a cyclic alkyl radical containing 3 to 6 carbon atoms,
- A is a valency bond or a --NR.sup.4 --CO-- or --CO--NR.sup.4 -- radical in which R.sup.4 is a hydrogen atom or a straight chain or branched, saturated or unsaturated radical containing 1 to 6 carbon atoms, or a cyclic alkyl radical containing 3 to 6 carbon atoms, and
- B is a straight chained or branched alkylene chain containing 1 to 8 carbon atoms, in which a --CH.sub.2 -- group can be replaced by a cycloalkylene radical containing 3 to 6 carbon atoms, an optically-active isomer thereof or a pharmaceutically acceptable salt thereof
- in an amount effective to exhibit nitrate-like activity for the prophylaxis or treatment of heart or circulatory disease,
- together with a pharmaceutically acceptable carrier.
- 7. A pharmaceutical composition according to claim 6, wherein R is a hydrogen atom; and H--(C.sub.1 -C.sub.3)-alkylene radical; an HO--(C.sub.1 -C.sub.3)-alkylene radical; an R.sup.1 R.sup.2 N--(C.sub.1 -C.sub.3) alkylene radical; an R.sup.1 R.sup.2 N--(C.sub.1 -C.sub.5)alkylenecarbonyl radical; an R.sup.1 R.sup.2 N--CO--NR.sup.3 --(C.sub.1 -C.sub.3) alkylene radical; an R.sup.1 R.sup.2 N--CO-- radical.
- 8. A pharmaceutical composition according to claim 6, wherein R.sup.1 is hydrogen, methyl, ethyl or isopropyl.
- 9. A pharmaceutical composition according to claim 6, wherein R.sup.2 is hydrogen, a C.sub.1 -C.sub.3 radical.
- 10. A pharmaceutical composition according to claim 6, wherein R.sup.3 is a hydrogen atom.
- 11. A pharmaceutical composition according to claim 6, wherein A is a valency bond, an --NH--CO-- group or an --CO--NH-- group.
- 12. A pharmaceutical composition according to claim 6, wherein B is a straight-chained or branched C.sub.1 -C.sub.5 -alkylene radical, or a cyclohexylene radical.
- 13. A pharmaceutical composition according to claim 6, wherein R is hydrogen or an H--(C.sub.1 -C.sub.8)-alkylene radical.
- 14. A pharmaceutical composition according to claim 6 comprising the compound 4-(2-nitroxyethyl)-piperidine.
- 15. A pharmaceutical composition according to claim 6 wherein said disease is angina pectoris.
- 16. A pharmaceutical composition suitable for the treatment of angina comprising a compound as claimed in claim 1 in an amount effective to exhibit nitrate-like activity,
- together with a pharmaceutically acceptable carrier.
- 17. A method of treatment of angina in a patient in said method comprising administrating to said patient an effective amount of a compound of claim 1.
- 18. A method for treatment of angina which comprises administering a composition according to claim 6 to a patient in need of such treatment.
- 19. A method for treatment of angina which comprises administering a therapeutically effective amount of a compound according to claim 6 to a patient in need of such treatment.
Priority Claims (1)
Number |
Date |
Country |
Kind |
3836084 |
Oct 1988 |
DEX |
|
Parent Case Info
This is a division, of application Ser. No. 424,451 filed Oct. 20, 1989, now U.S. Pat. No. 5,030,641.
US Referenced Citations (3)
Foreign Referenced Citations (2)
Number |
Date |
Country |
0280951 |
Mar 1975 |
EPX |
0101093 |
Feb 1984 |
EPX |
Non-Patent Literature Citations (4)
Entry |
Chemical Abstracts, vol. 106, No. 186566r (1988), pp. 688-689. |
Physical Organic Chemistry, vol. 97, 109228j (1982), p. 539. |
Chemical Abstracts, vol. 103, 141568y (1985), p. 686. |
Chemical Abstracts, vol. 104, 88398k (1986), p. 644. |
Divisions (1)
|
Number |
Date |
Country |
Parent |
424451 |
Oct 1989 |
|